Arsanis (NASDAQ: ASNS) and X4, two Boston-area biotech firms, agreed Tuesday morning to merge in a deal that will enable X4 to become a publicly traded company. The combined company will keep the X4 name and be led by X4’s president and CEO (and former Genzyme vet) Paula Ragan. Arsanis president and CEO Rene Russo has resigned to “pursue other opportunities,” the companies said in a statement.
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001, the Company’s CXCR4 antagonist, has been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced the successful completion of a $27 million Series B financing. Proceeds from the financing will be used to advance X4’s two lead drug candidates in clinical efficacy studies in immuno-oncology and a pivotal study in WHIM syndrome, a rare primary immunodeficiency disease. X4’s novel therapeutics are directed against the CXCR4 pathway to correct the trafficking of key immune cells that regulate healthy immune surveillance throughout the body.